HRTX - Heron Therapeutics, Inc.

NasdaqCM - NasdaqCM Real-time price. Currency in USD
Currency in USD

Valuation measures4

Market cap (intra-day) 134.08M
Enterprise value 230.99M
Trailing P/E N/A
Forward P/E N/A
PEG ratio (5-yr expected) N/A
Price/sales (ttm)1.11
Price/book (mrq)12.60
Enterprise value/revenue 2.03
Enterprise value/EBITDA -1.57

Trading information

Stock price history

Beta (5Y monthly) 0.92
52-week change 3-60.14%
S&P500 52-week change 32.72%
52-week high 35.6200
52-week low 31.0700
50-day moving average 31.9756
200-day moving average 32.9253

Share statistics

Avg vol (3-month) 32.58M
Avg vol (10-day) 32.23M
Shares outstanding 5119.72M
Implied shares outstanding 6N/A
Float 898.86M
% held by insiders 10.31%
% held by institutions 1102.54%
Shares short (14 May 2023) 421.65M
Short ratio (14 May 2023) 48.89
Short % of float (14 May 2023) 421.67%
Short % of shares outstanding (14 May 2023) 418.09%
Shares short (prior month 13 Apr 2023) 423.19M

Dividends & splits

Forward annual dividend rate 4N/A
Forward annual dividend yield 4N/A
Trailing annual dividend rate 30.00
Trailing annual dividend yield 30.00%
5-year average dividend yield 4N/A
Payout ratio 40.00%
Dividend date 3N/A
Ex-dividend date 4N/A
Last split factor 21:20
Last split date 312 Jan 2014

Financial highlights

Fiscal year

Fiscal year ends 30 Dec 2022
Most-recent quarter (mrq)30 Mar 2023


Profit margin -132.57%
Operating margin (ttm)-122.46%

Management effectiveness

Return on assets (ttm)-35.23%
Return on equity (ttm)-2,408.88%

Income statement

Revenue (ttm)113.83M
Revenue per share (ttm)1.01
Quarterly revenue growth (yoy)26.30%
Gross profit (ttm)-50.51M
EBITDA -136.51M
Net income avi to common (ttm)-150.9M
Diluted EPS (ttm)-1.3200
Quarterly earnings growth (yoy)N/A

Balance sheet

Total cash (mrq)60.02M
Total cash per share (mrq)0.5
Total debt (mrq)156.93M
Total debt/equity (mrq)N/A
Current ratio (mrq)2.29
Book value per share (mrq)-0.10

Cash flow statement

Operating cash flow (ttm)-127.87M
Levered free cash flow (ttm)-69.41M